Adamas Pharmaceuticals Inc (ADMS) Forecast, Price Target & Analyst Ratings

NASDAQ:ADMS

Current stock price

8.22
+0.06 (+0.74%)
At close:
8.3
+0.08 (+0.97%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Adamas Pharmaceuticals Inc (ADMS).

Forecast Snapshot

Consensus Price Target

Price Target
$8.69
+ 5.72% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Mar 1, 2022
Period
Q4 / 2021
EPS Estimate
-$0.18
Revenue Estimate
28.516M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
71.43%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.69
Upside
+ 5.72%
From current price of $8.22 to mean target of $8.69, Based on 14 analyst forecasts
Low
$8.08
Median
$8.67
High
$9.56

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for ADMS. The average price target is 8.69 null. This implies a price increase of 5.72% is expected in the next year compared to the current price of 8.22.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ADMS Current Analyst RatingADMS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

ADMS Historical Analyst RatingsADMS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
71.43%
ADMS was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about ADMS.
In the previous month the buy percentage consensus was at a similar level.
ADMS was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2021-11-17Northland Capital MarketsDowngrade Outperform -> Market Perform
2021-10-12JMP SecuritiesDowngrade Market Outperform -> Market Perform
2021-10-12Piper SandlerDowngrade Overweight -> Neutral
2021-10-12HC Wainwright & Co.Downgrade Buy -> Neutral
2021-10-11William BlairDowngrade Outperform -> Market Perform
2021-06-07HC Wainwright & Co.Maintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Mar 1, 2022
Period
Q4 / 2021
EPS Estimate
-$0.18
Revenue Estimate
28.516M
Revenue Q2Q
35.72%
EPS Q2Q
72.02%
Number of Analysts
11

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

ADMS is expected to report earnings on 3/1/2022. The consensus EPS estimate for the next earnings is -0.18 null and the consensus revenue estimate is 28.52M null.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2021 - 2025

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2018 2019 2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
ADMS revenue by date.ADMS revenue by date.
34.05M
5,873.68%		54.64M
60.47%		74.46M
36.27%		96.04M
28.98%		128.207M
33.49%		137.633M
7.35%		162.492M
18.06%		195.677M
20.42%
EBITDA
YoY % growth
ADMS ebitda by date.ADMS ebitda by date.
-113.56M
-30.92%		-91.03M
19.84%		-43.31M
52.42%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
ADMS ebit by date.ADMS ebit by date.
-115.02M
-30.81%		-92.24M
19.81%		-44.16M
52.12%		N/AN/AN/AN/AN/A
Operating Margin
ADMS operating margin by date.ADMS operating margin by date.
-337.80%-168.81%-59.31%N/AN/AN/AN/AN/A
EPS
YoY % growth
ADMS eps by date.ADMS eps by date.
-4.89
-23.48%		-3.80
22.29%		-2.02
46.84%		-1.04
48.66%		-0.36
64.81%		-0.18
51.20%		-0.28
-54.91%		-0.44
-58.00%

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 21 Q1 / 22 Q2 / 22 Q3 / 22 Q4 / 22 Q1 / 23 Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.18
72.02%		-0.17
53.72%		-0.13
53.41%		-0.07
70.29%		-0.03
82.91%		-0.13
20.41%		-0.05
59.46%		0.02
130.00%		0.10
433.33%
Revenue
Q2Q % growth		28.516M
35.72%		28.889M
49.61%		31.309M
42.49%		34.262M
32.31%		36.074M
26.51%		30.395M
5.21%		33.577M
7.25%		37.665M
9.93%		41.645M
15.44%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/AN/A

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ADMS Yearly Revenue VS EstimatesADMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADMS Yearly EPS VS EstimatesADMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
24.11%
EPS Next 5 Year
12.28%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
21.96%
Revenue Next 5 Year
20.86%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

Adamas Pharmaceuticals Inc / ADMS Forecast FAQ

Can you provide the average price target for Adamas Pharmaceuticals Inc stock?

14 analysts have analysed ADMS and the average price target is 8.69 null. This implies a price increase of 5.72% is expected in the next year compared to the current price of 8.22.

Can you provide the upcoming earnings date for Adamas Pharmaceuticals Inc?

Adamas Pharmaceuticals Inc (ADMS) will report earnings on 2022-03-01, after the market close.

What are the consensus estimates for Adamas Pharmaceuticals Inc (ADMS) next earnings?

The consensus EPS estimate for the next earnings of Adamas Pharmaceuticals Inc (ADMS) is -0.18 null and the consensus revenue estimate is 28.52M null.

What is the consensus rating for ADMS stock?

The consensus rating for Adamas Pharmaceuticals Inc (ADMS) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.